Comparison · NCT00274261-1cfcf389
C31G Vaginal Gel vs Conceptrol® Vaginal Gel: Incidence of Adverse Events.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. C31G Vaginal Gel vs Conceptrol® Vaginal Gel: Incidence of Adverse Events. Trial comparisons, record NCT00274261-1cfcf389. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00274261-1cfcf389
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.662 | 0.631 | 0.692 | wilson | |
| Risk in group 2 | 0.686 | 0.648 | 0.721 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0236 | -0.0703 | 0.024 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.966 | 0.9 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.898 | 0.724 | 1.11 | log | |
| Number needed to treat, for one fewer participant with the outcome on C31G Vaginal Gel than on Conceptrol® Vaginal Gel | 42.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | C31G Vaginal Gel | C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel~C31G: The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study. | 617 | 932 | OG000 |
| Group 2 | Conceptrol® Vaginal Gel | Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.~nonoxynol-9 (N-9): The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study. | 434 | 633 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of Adverse Events.
- Description
- Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.
- Time frame
- duration of the study - through 6 month or 12 months of use
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®
- NCT number
- NCT00274261
- Phases
- PHASE3
- Conditions
- Pregnancy
- Interventions
- C31G, nonoxynol-9 (N-9)
- Lead sponsor
- Premier Research
- Results first posted
- 2013-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00274261?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00274261-1cfcf389